Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations in an ongoing Phase 1/2 clinical study Monte Rosa plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 in combination with apalutamide targeting AR mutant patients in Q3 2026 BOSTON, March 16, 2026 (G ...